In silico screening, synthesis, characterization and biological evaluation of novel anticancer agents as potential COX-2 inhibitors-Reference-Cited by-同舟云学术

In silico screening, synthesis, characterization and biological evaluation of novel anticancer agents as potential COX-2 inhibitors

Published:2023-07-15 Issue:2 Volume:31 Page:119-133
ISSN:2008-2231
Container-title:DARU Journal of Pharmaceutical Sciences
language:en
Short-container-title:DARU J Pharm Sci

Author:

Sahu Ankita^ORCID,Pradhan Dibyabhaba^ORCID,Veer Babita^ORCID,Kumar Sumit,Singh Ram^ORCID,Raza Khalid^ORCID,Rizvi Moshahid A.^ORCID,Jain Arun Kumar^ORCID,Verma Saurabh^ORCID

Funder

Indian Council of Medical Research

Publisher

Springer Science and Business Media LLC

Subject

Applied Mathematics,General Mathematics

Link

https://link.springer.com/content/pdf/10.1007/s40199-023-00467-x.pdf

Reference63 articles.

1. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol. 2004;5: 241.

2. Clària J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9:2177–90.

3. Chow LWC, Loo WTY, Toi M. Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother. 2005;59(Suppl 2):281–4.

4. Botting RM, Botting JH. The discovery of COX-2. In: Pairet M, van Ryn J, editors. COX-2 Inhibitors [Internet]. Basel: Birkhäuser; 2004 [cited 2023 Jan 3]. p. 1–13. Available from: https://doi.org/10.1007/978-3-0348-7879-1_1.

5. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of Cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010;2010:e215158 (Hindawi).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023);Expert Opinion on Therapeutic Patents;2024-07-03

2. Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities;DARU Journal of Pharmaceutical Sciences;2024-04-29

3. In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma;Scientific Reports;2023-10-02